Pancreatic Neuroendocrine Microtumors (WHO 2022) Are Not Always Low-Grade Neoplasms: A Case with a Highly Increased Proliferation Rate
Authors:
Open Access
- 26 February 2024
- journal article
- case report
- Published by Springer Nature in Endocrine Pathology
- Vol. 35 (2) , 147-153
Abstract
Traditionally considered non-functional low proliferative benign neuroendocrine proliferations measuring less than 5 mm, pancreatic (neuro)endocrine microadenomas are now classified as pancreatic neuroendocrine microtumors in the 2022 WHO classification of endocrine and neuroendocrine tumors. This case report discussed the features of an incidentally identified 4.7-mm glucagon-expressing pancreatic neuroendocrine microtumor with MEN1 mutation only, chromosomally stable and an epigenetic alpha-like phenotype. The tumor was associated with an unexplained increased proliferation rate in Ki-67 of 15%. There was no associated DAXX/ATRX deficiency. The presented case challenges the conventional thought of a low proliferative disease of the so-called “pancreatic neuroendocrine microadenomas” and provides additional support to the 2022 WHO classification that also requires grading of these neoplasms. Despite exhibiting molecular features of less aggressive behavior, the case also underscores the biological complexity of pancreatic neuroendocrine microtumors. By recognizing the heterogenous spectrum of neuroendocrine neoplasms, the current case also contributes to ongoing discussions on how to optimize the clinical management of such tumors.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (188639)
- University of Bern
This publication has 17 references indexed in Scilit:
- Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic gradingLaboratory Investigation, 2022
- Overview of the 2022 WHO Classification of Paragangliomas and PheochromocytomasEndocrine Pathology, 2022
- Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse PrognosisEndocrine Pathology, 2021
- Significance of Alpha-inhibin Expression in Pheochromocytomas and ParagangliomasAmerican Journal of Surgical Pathology, 2021
- Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational StudyFrontiers in Medicine, 2020
- Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progressionCommunications Biology, 2020
- Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasisVirchows Archiv, 2018
- The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine TumorsEndocrine Pathology, 2016
- A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic CharacteristicsCancer Discovery, 2015
- Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progressionBritish Journal of Cancer, 2004